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Introduction {#sec001}
============

Sickle cell disease (SCD) is an inherited red blood cell disorder that affects approximately 1 in 365 African Americans at birth \[[@pone.0229710.ref001]\] and 25 million people worldwide.\[[@pone.0229710.ref002]\] Patients with SCD experience inferior health outcomes and have access to fewer health resources compared to other diseases.\[[@pone.0229710.ref003]\] A large majority of SCD patients are enrolled in Medicaid, which is accepted by less than 70% of physicians in the U.S.\[[@pone.0229710.ref003]\] Suboptimal coverage for disease-appropriate comprehensive care leads to patients with SCD relying on emergency room and inpatient hospitalization settings for their medical care.\[[@pone.0229710.ref003], [@pone.0229710.ref004]\]

In parallel with the lack of access to comprehensive care, there is a substantial economic burden for treating SCD patients in the emergency room and inpatient hospital settings. It is currently estimated that \$1.6 billion per year is spent in the United States of America on healthcare related-costs for SCD-related complications.\[[@pone.0229710.ref005]\] Approximately 81% of these costs are attributed to inpatient hospital care. Both health care related costs and health care utilization (HCU) increase with older age in SCD.\[[@pone.0229710.ref005], [@pone.0229710.ref006]\] New therapies under development may reduce the health disparities that SCD patients face and decrease patient morbidity and the financial burden to the health care system.

Until recently, hydroxyurea was the only FDA-approved therapy available to treat patients with SCD. Hydroxyurea reduces the rates of vaso-occlusive crises (VOC), acute chest syndrome, and red blood cell transfusion requirements \[[@pone.0229710.ref007]\] but the effects of hydroxyurea therapy on health care costs have been mixed.\[[@pone.0229710.ref008]--[@pone.0229710.ref011]\] Voxelotor is a recently FDA-approved therapy that improves hemoglobin concentration in patients with SCD, although its effects on SCD-related complications and HCU are unclear.\[[@pone.0229710.ref012]\] Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for SCD that has been predominantly applied in children due to concerns for higher rates of graft-versus host disease (GVHD) and lower rates of event-free and overall survival in adults.\[[@pone.0229710.ref013]\] In children, improvements in inpatient lengths of stay and health care costs are observed post-HSCT compared to pre-HSCT,\[[@pone.0229710.ref014], [@pone.0229710.ref015]\] although the cost benefit of HSCT compared to standard of care is not clear.\[[@pone.0229710.ref014]\] Furthermore, increased disease severity, which is in part defined by older age, and developing GVHD, are associated with poorer outcomes, increased costs, and HCU post-HSCT.\[[@pone.0229710.ref014], [@pone.0229710.ref015]\] The effects of HSCT on HCU and costs in SCD adults, who have greater SCD-related complications and a higher burden of care on the health care system than children,\[[@pone.0229710.ref005]\] have not been reported.

Recent advances using non-myeloablative conditioning regimens with an HLA-matched related donor have demonstrated that HSCT can be safely performed in SCD adults without a high rate of severe complications and with the achievement of an event-free survival \> 87% and overall survival \> 97%.\[[@pone.0229710.ref016], [@pone.0229710.ref017]\] Here we conducted a 2-year longitudinal analysis of adult SCD patients with similar characteristics, stratified by those who received a NMA HSCT versus those who did not, to assess whether HSCT improved the financial burden of care in SCD adults by comparing HCU and health care costs.

Methods {#sec002}
=======

The protocol was approved by the University of Illinois at Chicago (UIC) Institutional Review Board prior to conducting the research. We analyzed SCD patients receiving their routine medical care at the UIC Sickle Cell Center who were referred to the Blood & Marrow Transplant Clinic between August 2011 and April 2016. One hundred and twenty-six SCD patients meeting standard HSCT-eligibility criteria \[[@pone.0229710.ref018], [@pone.0229710.ref019]\] were referred during this time period, of which 83 were internal referrals and received their routine care at the UIC Sickle Cell Center. Patients who underwent a matched sibling donor HSCT received a non-myeloablative conditioning regimen with alemtuzumab and single dose total body irradiation 3 Gy as previously described.\[[@pone.0229710.ref017]\] Patients that did not proceed with HSCT continued on standard of care therapy according to their primary SCD physician's discretion.

In SCD patients undergoing HSCT, clinical data was collected one year before the HSCT date (pre-HSCT) and one and two years post-HSCT. In SCD patients that did not undergo HSCT, clinical data was collected one and two years after the transplant consultation date. Data collected included: rates of vaso-occlusive crises requiring medical attention, acute chest syndromes, strokes, and red blood transfusions. Emergency room or acute care center visits and inpatient hospital days were quantified during the respective time periods. Healthcare costs were extracted using Compass to gather all patient activity and Trendstar to gather the cost data. The cost data included costs for inpatient and outpatient fees, medications, and diagnostic and laboratory testing. Physician fees were not included in the Trendstar data. Inpatient hospital days and the costs of the HSCT procedure were included in the 1-year post-HSCT category.

Clinical data, HCU, and costs in the HSCT group were compared pre-HSCT to the 1^st^ and 2^nd^ year post-HSCT using a Wilcoxon matched-pairs signed rank test or paired t-test analysis for linear variables and the Chi square test for categorical variables. Comparisons between the HSCT group and the non-HSCT group were performed by the Mann Whitney test and Chi square test for linear and categorical variables, respectively. A P-value \< 0.05 was considered statistically significant. To determine clinical significance, odds ratios (OR) and β-values with 95% confidence intervals (CI) were calculated using logistic and linear regression analyses, respectively. Costs were log transformed for the linear regression analyses. Systat 11 (Systat Software Corporation, Chicago, IL, USA). Median and interquartile ranges (IQR) are provided.

Results {#sec003}
=======

Between August 2011 and April 2016, 83 SCD patients that received their routine medical care at our center were referred for HSCT. Of these, 16 proceeded with allogeneic HSCT while 67 did not. The reasons for not undergoing HSCT included lack of an HLA-matched related donor (n = 34, 51%), patient or family declining further work up for HSCT (n = 20, 30%), insurance denial (n = 11, 16%), or the presence of red blood cell antibodies to the potential donor (n = 2, 3%). The HSCT and non-HSCT SCD patients were similar with respect to age, sex, hemoglobin genotype, prior SCD-related therapy, and disease-related HSCT eligibility criteria ([Table 1](#pone.0229710.t001){ref-type="table"}). Of the 16 SCD patients that proceeded to HSCT, 13 (81%) had stable donor engraftment and no patients developed acute or chronic GVHD. The median inpatient cost attributed to the HSCT was \$92,666 (IQR, \$71,735--\$136,631) and the median length of hospitalization during the HSCT was 33 days (IQR, 24--30 days). The health care-related costs were greater in the first year post-HSCT (\$135,568, IQR \$114,840--\$205,853) compared to the year pre-HSCT (\$64,634, IQR \$24,354--\$102,588).

10.1371/journal.pone.0229710.t001

###### Baseline characteristics of patients with sickle cell disease that underwent hematopoietic stem cell transplantation (HSCT) vs. continued standard care.

![](pone.0229710.t001){#pone.0229710.t001g}

  --------------------------------------------------------------------------------------------------------------------------
  Clinical Variable                     Non-HSCT(n = 67)                     HSCT(n = 16)                        *P* Value
  ------------------------------------- ------------------------------------ ----------------------------------- -----------
  Age (years)                           34 (23--44)                          33 (24--34)                         0.2

  Male (%): Female (%)                  34%: 66%                             56%: 44%                            0.1

  Hb SS Genotype                        54 (81%)                             15 (94%)                            0.4

  Insurance Type                        Medicaid: 37 (55%)\                  Medicaid: 5 (31%)\                  0.2
                                        Medicare: 19 (28%)\                  Medicare: 8 (50%)\                  
                                        Private: 11 (16%)                    Private: 3 (19%)                    

  Sickle cell disease-related therapy   Hydroxyurea: 40 (60%)\               Hydroxyurea: 10 (63%)\              0.8\
                                        Chronic RBC transfusions: 15 (22%)   Chronic RBC transfusions: 5 (31%)   0.5

  HSCT eligibility criteria             ≥ 3 VOC/year: 61 (91%)\              ≥ 3 VOC/year: 14 (88%)\             0.7\
                                        ≥ 2 ACS/lifetime: 52 (78%)\          ≥ 2 ACS/lifetime: 12 (75%)\         0.8\
                                        Stroke: 17 (25%)                     Stroke: 4 (25%)                     1.0
  --------------------------------------------------------------------------------------------------------------------------

RBC, red blood cell; VOC, vaso-occlusive crisis; ACS, acute chest syndrome

Median (interquartile range) provided

Transplant eligibility criteria are associated with increased costs in SCD {#sec004}
--------------------------------------------------------------------------

Among all 83 HSCT and non-HSCT patients, the median cost of care in the year prior to HSCT or consultation was \$44,533 (IQR, \$16,151--\$126,473). Greater costs were observed in females versus males (\$74,135 vs. \$20,802; P = 0.004) (β 0.85, 95% CI: 0.15 to 1.54) and in those patients requiring chronic red blood cell transfusions (\$113,437 vs. \$31,120; P = 0.003) (β 1.08, 95% CI: 0.31 to 1.85). Statistically significant differences were not observed in costs by age (P = 0.2) (β 0.02, 95% CI: -0.01 to 0.05) ([Fig 1A](#pone.0229710.g001){ref-type="fig"}), hemoglobin genotype (HbSS: \$50,606 vs. non-HbSS: \$27,626; P = 0.2) (β 0.65, 95%CI: -0.25 to 1.57), hydroxyurea therapy (HU: \$49,103 vs. no HU: \$41,396; P = 0.8) (β -0.15, 95% CI: -0.92 to 0.62), or insurance type (Medicaid: \$42,315 vs. Medicare: \$67,689 vs. Private insurance: \$29,581; P = 0.3) (Private insurance vs. Medicaid or Medicare β -0.43, 95% CI: -1.34 to 0.48). Health care costs were directly associated with the number of inpatient days (β 0.03, 95% CI: 0.02 to 0.04) ([Fig 1B](#pone.0229710.g001){ref-type="fig"}). In addition, higher costs were observed in those SCD patients with ≥ 3 VOC versus \< 3 VOC (β 1.77, 95% CI: 1.19 to 2.35) ([Fig 1C](#pone.0229710.g001){ref-type="fig"}), acute chest syndrome versus no acute chest syndrome (β 0.66, 95% CI: 0.2 to 1.11) ([Fig 1D](#pone.0229710.g001){ref-type="fig"}), and stroke versus no stroke (stroke: \$134,112 vs. no stroke: \$41,144; P = 0.05) (β 1.43, 95% CI: -0.14 to 2.99) during that year.

![Clinical variables associated with health care costs in 83 patients with sickle cell disease in the year prior to evaluation for HSCT.](pone.0229710.g001){#pone.0229710.g001}

Reduced HCU and costs in the transplanted cohort second year post-transplant compared to year pre-transplant {#sec005}
------------------------------------------------------------------------------------------------------------

Compared to the year pre-HSCT, rates of red blood cell transfusions (2 units, IQR 0--26 units vs. 0 units, IQR 0--13 units, respectively; P = 0.005) (OR for transfusion 0.39, 95% CI: 0.09 to 1.78), vaso-occlusive crises (4 episodes, IQR 1--29 episodes vs. 0 episodes, IQR 0--37 episodes, respectively; P = 0.02) (OR for vaso-occlusive crisis 0.13, 95% CI: 0.02 to 0.75), and acute chest syndromes (31% of patients affected vs. 0% of patients affected, respectively; P = 0.02) (OR not calculatable), were lower by the 2^nd^ year post-HSCT ([Table 2](#pone.0229710.t002){ref-type="table"}). Consistent with the improvements in SCD-related complications, emergency room visits (OR for emergency room visit 0.07, 95% CI: 0.01 to 0.63) and inpatient hospital days (OR for hospitalization 0.14, 95% CI: 0.02 to 0.84) were also lower by the 2^nd^ year post-HSCT ([Fig 2](#pone.0229710.g002){ref-type="fig"}).

![Health care utilization.\
**(A)** Emergency visits improved from pre-HSCT (4 visits, IQR 2--6 visits) to 1 year (2 visits, IQR 0--3 visits) and 2 years post-HSCT (1 visit, IQR 0--4 visits). **(B)** The number of inpatients days increased from pre-HSCT (22 days, IQR 8--59 days) to 1 year post-HSCT (38 days, IQR 31--45 days) and then improved by the 2^nd^ year post-HSCT (1 day, IQR 0--22 days).](pone.0229710.g002){#pone.0229710.g002}

10.1371/journal.pone.0229710.t002

###### Sickle cell disease-related complications after hematopoietic stem cell transplantation (n = 16).

![](pone.0229710.t002){#pone.0229710.t002g}

  --------------------------------------------------------------------------------------------------------------
  Complication            Pre-HSCT\   Post- HSCT\   Post-HSCT\   *P* Value\              *P* Value\
                          1 Year      1^st^ Year    2^nd^ Year   (Year 1 vs. pre-HSCT)   (Year 2 vs. pre-HSCT)
  ----------------------- ----------- ------------- ------------ ----------------------- -----------------------
  RBC Transfusion         2 (0--26)   8 (6--16)     0 (0--13)    0.4                     0.005

  Vaso-occlusive crisis   4 (1--29)   2 (0--8)      0 (0--37)    0.1                     0.02

  Acute chest syndrome    5 (31%)     1 (6%)        0 (0%)       0.07                    0.02

  Stroke                  2 (13%)     0 (0%)        1 (6%)       0.1                     0.6
  --------------------------------------------------------------------------------------------------------------

13/16 had stable engraftment; 3/16 had secondary graft loss

HSCT, hematopoietic stem cell transplantation; RBC, red blood cell

Median (range) value provided

By the second year post-transplant, the health care-related costs were lower compared to the year pre-HSCT (pre-HSCT: \$64,634, IQR \$24,354 - \$102,588; 2^nd^ year post-HSCT: \$16,281, IQR \$5,471 to \$58,298; P = 0.01) (β -1.01, 95% CI: -1.95 to -0.05) with a median reduction of \$20,833/patient/year (IQR, -\$67,078--+\$4,442/patient/year). Health care related-costs were significantly lower in the 13 patients that had stable engraftment compared to the 3 patients with secondary graft loss at 1-year (\$123,796 vs. \$283,596, respectively; P = 0.02) (β -0.84, 95% CI: -1.55 to -0.13) and 2-years post-HSCT (\$7,471 vs. \$374,591, respectively; P = 0.004) (β -2.74, 95% CI: -4.44 to -1.05).

Reduced HCU and costs in the 2^nd^ year post-transplant compared to standard of care {#sec006}
------------------------------------------------------------------------------------

In the first year, we observed lower emergency room visits and increased inpatient hospital days in the HSCT versus non-HSCT group ([Fig 3](#pone.0229710.g003){ref-type="fig"}). By the second year, both emergency room visits (OR for emergency room visit 0.09, 95% CI: 0.02 to 0.34) and inpatient hospital days (OR for hospitalization 0.17, 95% CI: 0.05 to 0.55) were lower in the HSCT versus the non-HSCT group ([Fig 3](#pone.0229710.g003){ref-type="fig"}). Health care costs remained relatively stable in the year before, the first year after, and the second year after consultation in the non-HSCT group ([Fig 4](#pone.0229710.g004){ref-type="fig"}). Consistent with the HCU data, health care-related costs were higher in the first year post-transplant (HSCT: \$135,568, IQR \$114,840--\$205,583; non-HSCT: \$47,437, IQR \$15,264--\$140,375; P = 0.0004) (β 1.31, 95% CI: 0.66 to 1.97) but lower in the second year post-transplant (HSCT: \$16,281, IQR \$5,471--\$58,298; non-HSCT: \$54,082, IQR \$18,294--\$126,748; P = 0.05) (β -0.62, 95% CI: -1.51 to 0.28) compared to the non-HSCT group ([Fig 4](#pone.0229710.g004){ref-type="fig"}).

![Comparison of emergency care and inpatient hospital days in 16 transplanted and 67 non-transplanted patients with sickle cell disease.\
(A) At 1 year from transplantation or the time of referral in the non-transplanted patients, emergency visits were lower (2 visits, IQR 0--3 visits vs. 3 visits, IQR 1--7 visits, respectively) while inpatient hospital days were higher (38 days, IQR 30--45 days vs. 10 days, IQR 3--39 days, respectively) in the HSCT vs. non-HSCT groups. (B) By the 2^nd^ year, improvements in both emergency room visits (1 visit, IQR 0--4 visits vs. 3 visits, IQR 2--7 visits, respectively) and inpatients hospital days (1 day, IQR 0--22 days vs. 12 days, IQR 3--31 days, respectively) were observed in the HSCT vs. non-HSCT groups.](pone.0229710.g003){#pone.0229710.g003}

![Health care costs.\
**(A)** Health care costs remained relatively stable in the non-HSCT group from pre-referral (\$41,144, IQR \$14,590--\$126,508), 1 year post-referral (\$47,437, IQR \$15,264--\$140,375), and 2 years post-referral (\$54,082, IQR \$18,294--\$126,748). **(B)** Health care costs increased from pre-HSCT values (\$64,634, IQR \$24,354--\$102,588) to the 1^st^ year post-HSCT (\$135,568, IQR \$114,840--\$205,853) and then improved by the 2^nd^ year post-HSCT (\$16,281, IQR \$5,471--\$58,298).](pone.0229710.g004){#pone.0229710.g004}

Discussion {#sec007}
==========

Sickle cell disease causes acute and chronic complications that lead to substantial morbidity. The clinical course of SCD is further complicated by a lack of access to health care resources and treatment options. In a longitudinal cohort of adult SCD patients, we demonstrate that allogeneic HSCT using a nonmyeloablative conditioning approach leads to reduced SCD-related complications, HCU and costs by the second year post-HSCT compared to pre-HSCT values. Furthermore, we demonstrate that HCU and costs are lower in those SCD patients that proceeded to HSCT compared to SCD patients with similar SCD-related complications that did not undergo HSCT and continued on standard of care therapy.

It is estimated that the average cost of care for an adult with SCD ranges from \$21,720 to \$58,044 per year.\[[@pone.0229710.ref005], [@pone.0229710.ref020]\] Approximately 84% of these costs are attributed to SCD-related complications and 81% are due to costs incurred during hospitalizations.\[[@pone.0229710.ref005]\] Consistent predictors for increased HCU and costs in the literature have included older age, female gender, acute chest syndrome, stroke, red blood cell transfusions, public insurance, and the number of hospitalizations.\[[@pone.0229710.ref020]--[@pone.0229710.ref026]\] We found that the median cost of care for UIC adults with SCD in the year prior to referral for HSCT was \$44,533 with an interquartile range of \$16,151 --\$126,473. Higher costs of care were associated with red blood cell transfusion requirements and inpatient hospital days. Furthermore, common definitions for clinically aggressive SCD that warrant disease modifying therapy and are used as indicators for HSCT evaluation,\[[@pone.0229710.ref018], [@pone.0229710.ref019]\] such as ≥ 3 VOC/year, acute chest syndrome, and stroke, were associated with higher costs. Understanding the estimates and predictors for HCU and costs in high risk SCD adults may help guide cost analyses for emerging interventions, such as selectin inhibitors\[[@pone.0229710.ref027], [@pone.0229710.ref028]\] and gene therapy.\[[@pone.0229710.ref029]\]

New in our study is the finding that allogeneic HSCT using a nonmyeloablative conditioning approach with an HLA-matched sibling donor improves HCU and costs in adults with SCD as soon as two years after transplant. A recent outcome analysis of allogeneic HSCT in children with SCD showed 5-year event-free and GVHD-free survival rates of 93% and 86%, respectively.\[[@pone.0229710.ref013]\] This has led to improvements in inpatient hospital days\[[@pone.0229710.ref014]\] and costs\[[@pone.0229710.ref015]\] in SCD children pre-HSCT compared to after HSCT. However, no significant differences in health care related costs were observed between those SCD children that underwent HSCT compared to SCD children that did not undergo HSCT.\[[@pone.0229710.ref014]\] This differs from our longitudinal study in adult SCD patients and may be due to the use of HLA-matched siblings versus unrelated donors, using peripherally mobilized rather than cord blood stem cells, and the absence of acute and chronic GVHD with our nonmyeloablative HSCT approach.

In our cohort of SCD adults that were referred to our transplant clinic and received a transplant, we observed improvements in acute care utilization, inpatient hospital days, and health care costs by the second year post-HSCT compared to pre-HSCT levels. We also compared HCU and costs between the cohort of patients who underwent HSCT versus the cohort of SCD adults that were referred to transplant but did not proceed and received standard of care therapy. In these two cohorts, that were comparable with regards to age, insurance type, prior therapy, and SCD severity, we demonstrated that SCD adults undergoing HSCT had lower acute care utilization, inpatient hospital days, and health care costs by the second year post-transplant compared to those that continued with standard of care therapy. To our knowledge, this is the first reported analysis for the economic impact of HSCT in adults with SCD. Based on these results and on a reasonable expectation for an incremental cost benefit over a prolonged observation time, we believe that our results may help guide the decision process for policy makers and insurance providers. It is estimated that patients with SCD have \$695,000 of lost income over their lifetime due to SCD-related complications and early mortality.\[[@pone.0229710.ref030]\] Hematopoietic stem cell transplantation may help regain this lost income of individuals with SCD, on top of the suggested improvement in HCU, and this will need to be investigated in future studies.

Limitations to our study include that HCU and costs that were incurred outside of our institution were not included, although SCD patients that underwent HSCT almost exclusively received their post-HSCT care at our institution. Subgroup analyses based on age and sex will need to be conducted in larger cohorts. Future investigation in a multicenter study is warranted to investigate the long-term effects of HSCT on HCU and costs in adults with SCD.

In conclusion, allogeneic HSCT may lead to improvements in HCU and costs compared to standard-of-care therapy in high-risk SCD adults. With a nonmyeloablative HSCT approach, the costs of the HSCT can be offset by the reductions in HCU and costs after approximately six years and may lead to improvements in both the morbidity and the financial burden on the health care system in this high-risk SCD patient group. Patients with SCD have limited access to health resources and therapeutic interventions, leading to poor health outcomes. Our findings highlight a therapeutic intervention, allogeneic HSCT, which leads to improved health and reduced health care utilization in the emergency room and inpatient settings for patients with SCD. Developing strategies to overcome barriers to allogeneic HSCT may help improve the health equity in patients with SCD.

We thank the individuals for their participation in this study as well as the staff and transplant coordinators for their efforts.

10.1371/journal.pone.0229710.r001
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Reviewer \#2: 1. The authors have done a fair job in presenting the data. Authors have described the statistical analyses used on the data, but did not indicate the level of significance when comparing different groups on the data. Although the P values are mentioned absence of indication of level of significance leads to undermining and confusion of the data presented. In a study that focuses on comparison of clinical data over a period of time, analyses and representation needs to be precise and clearly stated.

2\. Clinical level of significance should be mentioned in all the data that is presented.

3\. Is there a reason why there were greater costs observed in female group of patients versus male group of patients? Did the authors compare HSCT Vs non HSCT patients based on gender?

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Jehad Almasri

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Reviewer \#1:

1- For the conclusion, I recommend to adjust the language the conclusion to be as following: "In conclusion, allogeneic HSCT may leads to improvements in health care utilization and costs compared to standard-of-care therapy in high risk SCD adults." Given the relative small size and the need of multicenter study to replicate these findings before providing a such strong recommendation.

Thank you for this recommendation. As suggested, we have changed our language in the conclusion (page 13, 3rd paragraph, 1st sentence).

2- In abstract, "HSCT" needs to be defined for one time in the beginning.

We have provided the definition for HSCT in the abstract (page 3, 2nd sentence).

3- This article published in JAMA recently which underscores the need for disease-modifying therapies to improve the underlying morbidity and mortality associated with SCD. You might use it to justify the importance of transplant as a disease modifying therapy and how could improve the lifetime income of individuals with SCD on top of the suggested improvement in HCU in the current presented evidence (economic benefits on multiple levels). <https://hes32-ctp.trendmicro.com:443/wis/clicktime/v1/query?url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjamanetworkopen%2ffullarticle%2f2755485%3futm%5fsource%3dsilverchair%26utm%5fmedium%3demail%26utm%5fcampaign%3darticle%5falert%2djamanetworkopen%26utm%5fcontent%3dmthlyforyou%26utm%5fterm%3d120819%26term%3d120819&umid=3f7b50fa-59c4-41b9-913d-a3736bdaf5f3&auth=85c5a955287d1e42fab58bed777dfa626e5ad059-916f504479157f4df090472dc4676f843ea59603>

We appreciate the reviewer providing this important reference, which we have now included in the discussion as an additional potential benefit of transplantation in patients with SCD (page 13, 1st paragraph, 1st and 2nd sentences).

4- In the introduction, hydroxyurea is mentioned as the only FDA approved therapy available to treat patients with SCD. Now, since voxelotor has been recently approved by FDA in November 22, 2019 (which I understand that happened after submitting this manuscript), I highly recommend to comment on this medication and the related benefits as another option for patients with SCD.

In agreement, we have included voxelotor as a recently FDA-approved therapy to the introduction (page 4, 3rd paragraph, 3rd sentence).

5- I recommend to define more in the inclusion criteria the exact meaning of "match related HSCT". Does that mean matched sibling or matched parents or other related family members or combination of all of them? And I recommend to report the percentage of each category in case we have a combination.

To clarify the inclusion, we have changed the terminology to matched sibling donor in the methods section (page 6, 1st paragraph, 4th sentence). All of the donors were matched sibling donors.

6- It is unclear the age range that included in this study. The authors reported median and interquartile range (IQR). The IQR for HSCT group is 16-51. I assume this means there are some children who aged less than 16 and included in this study. I recommend to clarify this point to know what kind of population we are dealing with in this study and to report the percentages of children (less than or equals 16) and adults (more than 16).

Thank you for bringing up this error -- we had accidentally provided the range (16 -- 51 years) in the prior draft and have corrected the table to provide the interquartile range (24 -- 34 years) in the revised draft (page 19, Table 1). All of the patients in this analysis are age 16 or older.

7- The current literature suggests that myeloablative conditioning has good outcomes on survival, GVHD and engraftment with even possible superiority of myeloablative over nonmyeloablative/reduced intensity conditioning (RIC) in children population and subsequently possible less burden on health care system, whereas nonmyeloablative has better outcomes in adults. I suggest to put a rationale for limiting the data on RIC since we are talking about possible combined population in this evidence.

Because this analysis is predominantly an adult cohort (all age 16 or older), we have focused on those conditioning regimens that have demonstrated safety and efficacy in adults with SCD and avoided discussion on myeloablative vs. nonmyeloablative/RIC regimens in children populations. As mentioned above in item \#6, this was not a combined population of children and adults.

8- Proceeded not proceed in page 11, line 8.

We have changed "proceed" to "proceeded" (page 11, 1st paragraph, 4th sentence).

9- In the legend of figure 1, I suggest to clarify the population and the time frame you are trying to investigate. I believe these outcomes reported on all patients in the year prior to HSCT based on the results section.

Thank for bringing up this suggestion. We have clarified the population (all 83 patients) and the time frame (in the year prior to evaluation for transplantation) in the figure legend (page 18).

Reviewer \#2:

1\. The authors have done a fair job in presenting the data. Authors have described the statistical analyses used on the data, but did not indicate the level of significance when comparing different groups on the data. Although the P values are mentioned absence of indication of level of significance leads to undermining and confusion of the data presented. In a study that focuses on comparison of clinical data over a period of time, analyses and representation needs to be precise and clearly stated.

Thank you for this comment and in the revised manuscript, we have provided the level of statistical significance for the analyses in the methods section (page 7, 1st paragraph, 3rd sentence).

2\. Clinical level of significance should be mentioned in all the data that is presented.

As recommended, we have included measures of clinical significance (odds ratios for clinical outcomes, and beta values for cost as a linear variable). The methods for determining the clinical levels of significance are provided (page 7, 1st paragraph, 4th sentence) and the corresponding values have been provided in all of the relevant data in the results sections.

3\. Is there a reason why there were greater costs observed in female group of patients versus male group of patients? Did the authors compare HSCT Vs non HSCT patients based on gender?

In this study, it is not clear why there were greater costs in females versus males. This may be due to either selection bias or a true biological difference. We have included in the discussion that this will need to be investigated further in larger, cohorts (page 13, 2nd paragraph, 2nd sentence).

10.1371/journal.pone.0229710.r003
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Dear Dr. Saraf,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Senthilnathan Palaniyandi, Ph.D

Academic Editor
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Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Two minor points:

1- The conclusion language need to be modified in the abstract as well.

2- I would still highly recommend to add the actual age range in the manuscript. I understand your range is 16-51 but I do not see this has been mentioned any where in the manuscript.

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Jehad Almasri

Reviewer \#2: No
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I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.
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